文献速递流行病学与生物统计新药、器械与细胞基因治疗研发真实世界研究与卫生经济

监禁人群阿片类药物治疗、干预与结局的系统综述

Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
PubMed 文献 · PLoS Med · 2019-12-31

该系统综述检索2008年1月至2019年10月共8个数据库,纳入46项研究,评估监禁前、中、后阿片类干预。美沙酮或丁丙诺啡/纳洛酮治疗与较低非法阿片使用、更高治疗依从性、较少再监禁和更低死亡率相关;释放后立即OAT及纳洛酮分发可降低过量与死亡。

要点

  • 监禁期间美沙酮或丁丙诺啡/纳洛酮治疗可减少非法阿片使用并提高依从性。
  • 监禁期间OAT与较少非致死性过量和较低死亡率相关。
  • 释放后立即OAT及纳洛酮分发可显著降低阿片相关过量与死亡。

核心结论

  • 监禁机构应扩大阿片激动剂治疗(OAT),以降低阿片相关过量与死亡、减少非法使用并改善释放后治疗留存。
  • 释放后立即OAT及向高危个体分发纳洛酮可大幅减少阿片相关过量与死亡。

研究设计与样本

  • 系统综述检索8个电子数据库2008年1月至2019年10月发表的同行评议原创文献。
  • 纳入46项研究:22项随机对照试验、3项非随机临床试验和21项观察性研究。
  • 研究对象为监禁中或释放后≤90天的成人阿片使用障碍(OUD)患者。
  • 研究地域:北美30项、欧洲9项、亚洲/大洋洲7项。

主要发现

  • 在监禁机构接受美沙酮维持治疗(MMT)或丁丙诺啡/纳洛酮(BPN/NLX)者非法阿片使用率更低、OUD治疗依从性更高。
  • 接受MMT或BPN/NLX者再监禁可能性更低,释放后1年更可能工作。
  • 监禁期间接受MMT或BPN/NLX者非致死性过量更少、死亡率更低。

关键数值与推荐

  • 8项观察性研究使用行政数据,样本量中位数10,419例(范围2,273–131,472)。
  • 13项观察性研究使用原始数据,样本量中位数140例(范围27–960)。
  • 随机对照试验样本量中位数198例(范围15–1,557),非随机临床试验中位数44例(范围27–382)。
  • 多数研究参与者为中年成人(36–55岁)。

临床怎么用

  • 监禁机构应扩大OAT覆盖,而非仅采用戒断策略。
  • 释放后应立即启动OAT,并向高危个体分发纳洛酮。
  • 应在监禁前、中、后连续提供OAT和过量预防策略。

局限性

  • 研究异质性高(设计、场所、人群、治疗和结局不同),无法进行荟萃分析。
  • 关于监禁女性OUD患者的数据不足。
  • 缺乏未纳入已发表研究的监禁OUD人群信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Worldwide opioid-related overdose has become a major public health crisis. People with opioid use disorder (OUD) are overrepresented in the criminal justice system and at higher risk for opioid-related mortality. However, correctional facilities frequently adopt an abstinence-only approach, seldom offering the gold standard opioid agonist treatment (OAT) to incarcerated persons with OUD. In an attempt to inform adequate management of OUD among incarcerated persons, we conducted a systematic review of opioid-related interventions delivered before, during, and after incarceration. METHODS AND FINDINGS: We systematically reviewed 8 electronic databases for original, peer-reviewed literature published between January 2008 and October 2019. Our review included studies conducted among adult participants with OUD who were incarcerated or recently released into the community (≤90 days post-incarceration). The search identified 2,356 articles, 46 of which met the inclusion criteria based on assessments by 2 independent reviewers. Thirty studies were conducted in North America, 9 in Europe, and 7 in Asia/Oceania. The systematic review included 22 randomized control trials (RCTs), 3 non-randomized clinical trials, and 21 observational studies. Eight observational studies utilized administrative data and included large sample sizes (median of 10,419 [range 2273-131,472] participants), and 13 observational studies utilized primary data, with a median of 140 (range 27-960) participants. RCTs and non-randomized clinical trials included a median of 198 (range 15-1,557) and 44 (range 27-382) participants, respectively. Twelve studies included only men, 1 study included only women, and in the remaining 33 studies, the percentage of women was below 30%. The majority of study participants were middle-aged adults (36-55 years). Participants treated at a correctional facility with methadone maintenance treatment (MMT) or buprenorphine (BPN)/naloxone (NLX) had lower rates of illicit opioid use, had higher adherence to OUD treatment, were less likely to be re-incarcerated, and were more likely to be working 1 year post-incarceration. Participants who received MMT or BPN/NLX while incarcerated had fewer nonfatal overdoses and lower mortality. The main limitation of our systematic review is the high heterogeneity of studies (different designs, settings, populations, treatments, and outcomes), precluding a meta-analysis. Other study limitations include the insufficient data about incarcerated women with OUD, and the lack of information about incarcerated populations with OUD who are not included in published research. CONCLUSIONS: In this carefully conducted systematic review, we found that correctional facilities should scale up OAT among incarcerated persons with OUD. The strategy is likely to decrease opioid-related overdose and mortality, reduce opioid use and other risky behaviors during and after incarceration, and improve retention in addiction treatment after prison release. Immediate OAT after prison release and additional preventive strategies such as the distribution of NLX kits to at-risk individuals upon release greatly decrease the occurrence of opioid-related overdose and mortality. In an effort to mitigate the impact of the opioid-related overdose crisis, it is crucial to scale up OAT and opioid-related overdose prevention strategies (e.g., NLX) within a continuum of treatment before, during, and after incarceration.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Malta M, Varatharajan T, Russell C, et al. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. PLoS Med. 2019. PMID: 31891578. doi:10.1371/journal.pmed.1003002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。